How does the Philadelphia chromosome relate to Chronic Myeloid Leukemia, and why is it important for my diagnosis?

The Philadelphia chromosome is an acquired genetic rearrangement that is the defining characteristic and driver of CML. It results in the overproduction of abnormal white blood

What are the early warning signs of Chronic Myeloid Leukemia (CML), especially since it's often found incidentally?

In its early, chronic phase, CML often presents with mild or no symptoms, and many individuals are diagnosed during routine blood tests for other conditions. When symptoms do occur, they are typically vague and worsen slowly. These can include fatigue, weight loss, night sweats, or a feeling of fullness under the ribs due to an enlarged spleen.

Chronic Myeloid Leukemia

Chronic myeloid leukemia is a slow-growing blood cancer characterized by the overproduction of white blood cells, driven by an acquired genetic rearrangement known as the Philadelphia chromosome.

Overview

Chronic myeloid leukemia is a slow-growing cancer of the blood-forming tissue (bone marrow). Normal bone marrow produces red blood cells (erythrocytes) to carry oxygen, white blood cells (leukocytes) to protect against infection, and platelets (thrombocytes) involved in blood clotting. In chronic myeloid leukemia, the bone marrow produces too many white blood cells.

Initially, these abnormal white blood cells function relatively normally. However, as the disease progresses, immature white blood cells called myeloblasts (or blasts) accumulate in the blood and bone marrow. This overgrowth impairs the development of other blood cells, leading to a shortage of red blood cells (anemia) and platelets.

The condition usually begins after age 60. About half of all affected individuals do not initially show symptoms and are diagnosed during routine blood tests performed for other reasons.

Frequency

Chronic myeloid leukemia occurs in approximately 1 in 555 individuals and accounts for about 10 percent of all blood cell cancers (leukemias).

Phases and Symptoms

Chronic myeloid leukemia progresses through three distinct phases, with symptoms worsening as the disease advances:

The Chronic Phase

During this phase, the number of mature white blood cells is elevated, and myeloblasts account for less than 10 percent of blood cells. Symptoms are typically mild or absent and worsen very slowly. This phase can last from months to years.

The Accelerated Phase

In this phase, myeloblasts make up 10 to 29 percent of blood cells, and symptoms continue to worsen. This phase typically lasts 4 to 6 months, though it is skipped in some individuals.

The Blast Phase (Blast Crisis)

In blast crisis, 30 percent or more of the blood or bone marrow cells are myeloblasts. Symptoms are most severe during this phase and can include:

Excessive tiredness (fatigue)
Fever
Weight loss
A massively enlarged spleen (splenomegaly), causing abdominal fullness and loss of appetite
Bone pain
Life-threatening complications, including serious infections and uncontrolled bleeding

Causes & Genetic Factors

Chronic myeloid leukemia is caused by a rearrangement (translocation) of genetic material between chromosome 9 and chromosome 22. This translocation, written as t(9;22), fuses part of the ABL1 gene from chromosome 9 with part of the BCR gene from chromosome 22, creating an abnormal fusion gene called BCR-ABL1.

The abnormal chromosome 22 containing this fusion gene is known as the Philadelphia chromosome. This genetic change is a somatic mutation, meaning it is acquired during a person's lifetime and is present only in abnormal blood cells; it is not inherited.

The normal ABL1 protein is involved in cell growth, division, maturation, movement, and self-destruction (apoptosis). The abnormal BCR-ABL1 fusion protein constantly signals cells to divide abnormally and blocks them from self-destructing, without requiring cellular signals to turn it on. This leads to the overproduction of abnormal cells and a shortage of normal blood cells. The Philadelphia chromosome serves as a key target for molecular therapies.

In 5 to 10 percent of cases, the BCR-ABL1 fusion gene is created by complex rearrangements involving other chromosomes in addition to 9 and 22, known as variant Philadelphia translocations. These cases behave similarly to those caused by t(9;22).

Progression from the chronic phase to the accelerated and blast phases is believed to be driven by additional somatic mutations. Common genetic changes associated with blast crisis include:

An extra copy of chromosome 8 (trisomy 8)
An abnormality of chromosome 17 known as isochromosome 17
An extra copy (duplication) of the Philadelphia chromosome

Inheritance

This condition is not inherited. It arises from a somatic mutation in the body's cells that occurs after conception.

Other Names for This Condition

CGL
Chronic granulocytic leukemia
Chronic myelocytic leukemia
Chronic myelogenous leukemia
CML